European Respiratory Journal最新文献_第5页

Reduction in sputum inflammatory cells after a single dose of cepeprubart in COPD patients. 慢性阻塞性肺病患者单剂量头孢普巴特后痰炎细胞的减少。

IF 24.3 1区医学

European Respiratory Journal Pub Date : 2025-09-11 DOI: 10.1183/13993003.01295-2025

Dave Singh,Thomas Southworth,Alex Mulvanny,Nick Stefanko,Amy Ascher,Russell P Rother

引用次数: 0

European Respiratory Society statement on advanced telemedicine for obstructive sleep apnoea (e-Sleep). 欧洲呼吸学会关于阻塞性睡眠呼吸暂停（e-Sleep）先进远程医疗的声明。

IF 24.3 1区医学

European Respiratory Journal Pub Date : 2025-09-04 DOI: 10.1183/13993003.00557-2025

Johan Verbraecken,Emanuele Amodio,Ozen K Basoglu,Riccardo Bellazzi,Matteo Bradicich,Marie Bruyneel,Refika Hamutcu Ersu,Francesco Fanfulla,Brigitte Fauroux,Ludger Grote,Carolina Lombardi,Walter T McNicholas,Carla Miltz,Yüksel Peker,Sofia Schiza,Monique Carolina Suarez,Renaud Tamisier,Hui-Leng Tan,Dries Testelmans,Thomy Tonia,Piet-Heijn van Mechelen,Bart Vrijsen,Maria R Bonsignore

{"title":"European Respiratory Society statement on advanced telemedicine for obstructive sleep apnoea (e-Sleep).","authors":"Johan Verbraecken,Emanuele Amodio,Ozen K Basoglu,Riccardo Bellazzi,Matteo Bradicich,Marie Bruyneel,Refika Hamutcu Ersu,Francesco Fanfulla,Brigitte Fauroux,Ludger Grote,Carolina Lombardi,Walter T McNicholas,Carla Miltz,Yüksel Peker,Sofia Schiza,Monique Carolina Suarez,Renaud Tamisier,Hui-Leng Tan,Dries Testelmans,Thomy Tonia,Piet-Heijn van Mechelen,Bart Vrijsen,Maria R Bonsignore","doi":"10.1183/13993003.00557-2025","DOIUrl":"https://doi.org/10.1183/13993003.00557-2025","url":null,"abstract":"Telemedicine (TM) as a means of remote patient-physician interaction is gaining popularity in nearly every field, and (respiratory) sleep medicine is no exception. Because obstructive sleep apnoea (OSA) is a chronic condition, and requires a continuous treatment and monitoring of therapy success, telematic communications could be useful to establish diagnostic and therapeutic strategies. This Statement summarises the evidence and efficacy of TM options in OSA. An interdisciplinary European Respiratory Society (ERS) Task Force (TF) evaluated the scientific literature based on a systematic search and two step screening process (title/abstract and full text). Although the TF does not make recommendations for clinical practice, it describes its current practice of TM applications in OSA. Literature shows that TM has been studied in different areas of OSA management, with potential benefits. TM also served as a major research tool to provide big data related to PAP therapy. TM results in similar or improved compliance when compared with traditional face-to-face encounters. TM-based targeted troubleshooting and support based on individual patient data, and a combination via smartphone apps or coaching websites, are feasible and effective. Expanding evidence suggests that TM is likely cost-effective. However, data do not consistently support staff time savings through TM-based solutions. The potential benefits of TM include improved access to health care, and increased adherence to (chronic illness) treatment plans. Benefits should be weighed against the overall costs of TM and risks related to suboptimal compliance.","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":"136 1","pages":""},"PeriodicalIF":24.3,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144995624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pregnancy, asthma and exacerbations: a population-based cohort. 妊娠、哮喘和加重：一个基于人群的队列。

IF 21 1区医学

European Respiratory Journal Pub Date : 2025-08-28 DOI: 10.1183/13993003.01327-2025

Bohee Lee, Ernie Wong, Tricia Tan, Hitasha Rupani, Chloe I Bloom

{"title":"Pregnancy, asthma and exacerbations: a population-based cohort.","authors":"Bohee Lee, Ernie Wong, Tricia Tan, Hitasha Rupani, Chloe I Bloom","doi":"10.1183/13993003.01327-2025","DOIUrl":"https://doi.org/10.1183/13993003.01327-2025","url":null,"abstract":"Background: Asthma exacerbations during pregnancy are associated with adverse maternal and perinatal outcomes. Identifying modifiable risk factors are essential for improving health outcomes. We aimed to describe exacerbation patterns during pregnancy and identify exacerbation risk factors, particularly modifiable risk factors such as inhaled corticosteroid (ICS) use.Methods: A cohort study using UK primary care and hospital data (2004-2020) to identify pregnant women with asthma. Exacerbations were defined as a short course of oral corticosteroids, emergency department visit, or unscheduled hospital admission. Multivariable logistic regression was used to assess associations between maternal characteristics and exacerbations (primary outcome) and ICS use (secondary outcome).Results: Among 40 196 pregnant women with asthma, total exacerbations declined by ∼30% during pregnancy. However, exacerbations associated with hospital admission increased by 30-45% during the second and third trimesters, declining abruptly after delivery. ICS prescriptions were reduced in 31% of women during pregnancy. Decreased ICS use was associated with suboptimal asthma control pre-pregnancy, age, ethnicity and smoking. The strongest exacerbation risk factors were a history of exacerbations (adjusted-OR, 95% CI: 4.09, 3.81-4.39), reduced ICS during pregnancy (2.29, 2.12-2.47) and ≥4 prescriptions/year for ICS+another-preventer before pregnancy (2.11, 1.87-2.37). Additional risk factors included blood eosinophilia, smoking and obesity.Conclusions: Despite fewer total exacerbations, exacerbations associated with a hospital admission increased during pregnancy. One-third of women reduced ICS use during pregnancy, yet this was the second largest exacerbation risk factor, and completely modifiable. Other major risk factors were type-2 inflammation and another modifiable risk factor, suboptimal asthma control pre-pregnancy.","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Linezolid for the treatment of drug-resistant tuberculosis. 利奈唑胺用于治疗耐药结核病。

IF 24.3 1区医学

European Respiratory Journal Pub Date : 2025-08-22 DOI: 10.1183/13993003.00927-2025

Christoph Lange,Clifton Barry,Giovanni Sotgiu

引用次数: 0

Post-tuberculosis lung disease: questions and answers. 结核后肺病：问答。

IF 21 1区医学

European Respiratory Journal Pub Date : 2025-08-22 Print Date: 2025-08-01 DOI: 10.1183/13993003.00992-2025

Giovanni Battista Migliori, Rosella Centis, Lia D'Ambrosio, Denise Rossato Silva, Daria Podlekareva, H Simon Schaaf

引用次数: 0

European Respiratory Society and European Sleep Research Society statement on the treatment of central sleep apnoea with adaptive servo-ventilation. 欧洲呼吸学会和欧洲睡眠研究学会关于自适应伺服通气治疗中枢性睡眠呼吸暂停的声明。

IF 21 1区医学

European Respiratory Journal Pub Date : 2025-08-22 Print Date: 2025-08-01 DOI: 10.1183/13993003.00263-2025

Winfried J Randerath, Sophia E Schiza, Michael Arzt, Maria Rosaria Bonsignore, Raphael Heinzer, Carolina Lombardi, Robert Lyssens, Gianfranco Parati, Thomas Penzel, Jean Louis Pepin, Dirk Pevernagie, Silke Ryan, Luca Vignatelli, Esther I Schwarz

{"title":"European Respiratory Society and European Sleep Research Society statement on the treatment of central sleep apnoea with adaptive servo-ventilation.","authors":"Winfried J Randerath, Sophia E Schiza, Michael Arzt, Maria Rosaria Bonsignore, Raphael Heinzer, Carolina Lombardi, Robert Lyssens, Gianfranco Parati, Thomas Penzel, Jean Louis Pepin, Dirk Pevernagie, Silke Ryan, Luca Vignatelli, Esther I Schwarz","doi":"10.1183/13993003.00263-2025","DOIUrl":"10.1183/13993003.00263-2025","url":null,"abstract":"Adaptive servo-ventilation (ASV) has been considered effective in controlling various forms of central sleep apnoea (CSA) and also any additional obstructive sleep apnoea (OSA) component. However, after the publication of the SERVE-HF study, its use was restricted in patients with systolic heart failure (HF) and prevalent CSA, and was withheld from many patients with symptomatic CSA. In the meantime, the devices have been further developed and the algorithms adapted, and there is new evidence from randomised controlled trials and observational studies that makes it necessary to re-evaluate some societies' statements on the use of ASV, especially in patients with HF and CSA and with the current ASV devices. This short statement is based on a review of the effect of ASV on hard cardiovascular end-points, echocardiographic parameters and exercise capacity as well as on sleep architecture and sleep quality, symptoms and quality of life (QoL) in patients with congestive HF. The expert group concludes that ASV has positive effects on CSA and QoL in various forms of CSA, that current ASV devices have no negative effect on hard cardiovascular end-points, and that ASV has positive effects on patient-reported outcomes. Moreover, it is used by Task Force members after optimal treatment of the underlying disease and after an unsuccessful continuous positive airway pressure trial in patients with HF with preserved ejection fraction, but also in patients with left ventricular ejection fraction 30-45%. In the latter group, however, initiation is performed in expert centres only. In severe systolic HF, ASV is sometimes evaluated in a palliative therapy concept for severely symptomatic patients with CSA.","PeriodicalId":12265,"journal":{"name":"European Respiratory Journal","volume":" ","pages":""},"PeriodicalIF":21.0,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiopulmonary exercise testing unmasks right ventricular failure in pulmonary arterial hypertension risk stratification: time to reframe the role of the 6-minute walk test? 心肺运动试验揭示肺动脉高压风险分层中的右心衰：是时候重新定义6分钟步行试验的作用了？

IF 24.3 1区医学

European Respiratory Journal Pub Date : 2025-08-22 DOI: 10.1183/13993003.00849-2025

Andrew Constantine,Konstantinos Dimopoulos,Colm McCabe

引用次数: 0

Beyond predictive accuracy: interpreting feature importances in pulmonary endarterectomy risk models with total correlation analysis. 超越预测准确性：用全相关分析解释肺内膜切除术风险模型中特征的重要性。

IF 24.3 1区医学

European Respiratory Journal Pub Date : 2025-08-22 DOI: 10.1183/13993003.00893-2025

Yoshiyasu Takefuji

引用次数: 0

Adaptive servo-ventilation for central sleep apnoea in heart failure: where are we? 自适应伺服通气治疗心力衰竭中枢性睡眠呼吸暂停：进展如何？

IF 24.3 1区医学

European Respiratory Journal Pub Date : 2025-08-22 DOI: 10.1183/13993003.00976-2025

Patrick Lévy

引用次数: 0

Just like good wine, European bronchiectasis deserves regional denominations. 就像好酒一样，欧洲的支气管扩张也应该有地区名称。

IF 24.3 1区医学

European Respiratory Journal Pub Date : 2025-08-22 DOI: 10.1183/13993003.01020-2025

Keshav Mangalick,Leopoldo N Segal

引用次数: 0